Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-5 extending, end-of-life (EoL) treatments imply that health gains from such treatments are 6 valued more than other health gains. Despite claims that the policy is supported by societal 7 values, evidence from preference elicitation studies is mixed and in-depth research has 8 shown there are different societal viewpoints. Few studies elicit preferences for policies 9 directly or combine different approaches to understand preferences. 10 11 Survey questions were designed to investigate support for NICE EoL guidance at national 12 and regional levels. These 'Decision Rule' and 'Treatment Choice' questions were 13 administered to an online sample of 1,496 UK respondents in May 2014. The same 14 respondents answered questions designed to elicit their agreement with three viewpoints 15 (previously identified and described) in relation to provision of EoL treatments for terminally 16 ill patients. We report the findings of these choice questions and examine how they relate 17 to each other and respondents' viewpoints. 18 19 The Decision Rule questions described three policies: DA -a standard 'value for money' 20 test, applied to all health technologies; DB -giving special consideration to all treatments 21 for terminal illnesses; and DC -giving special consideration to specific categories of 22 treatments for terminal illnesses e.g. life extension (as in NICE EoL guidance) or those that 23 10 11
improve quality-of-life (QoL). Three Treatment Choices were presented: TA -improving QoL 1 for patients with a non-terminal illness; TB -extending life for EoL patients; and TC -2 improving QoL at the EoL. 3 4 DC received most support (45%) with most respondents giving special consideration to EoL 5 only when treatments improved QoL. The most commonly preferred treatment choices 6 were TA (51%) and TC (43%). Overall, this study challenges claims about public support for 7 NICE's EoL guidance and the focus on life extension at EoL and substantiates existing 8 evidence of plurality in societal values. 9 Introduction 1 In 2009 the National Institute of Health and Care Excellence (NICE) issued supplementary 2 guidance for the appraisal of life-extending, end-of-life (EoL) treatments (NICE, 2009 ). This 3 guidance permits such treatments to be recommended, even if they are not cost-effective 4 according to usual standards, if certain criteria are met. These criteria are: 1) the treatment 5 is for patients with short life expectancy normally less than 24 months, 2) the treatment 6 would offer an extension to life of at least 3 months, and 3) the treatment is licensed for a 7 small patient population (NICE, 2009 ). NICE, like other national Health Technology 8 Assessment (HTA) organisations, has adopted an approach to economic evaluation based on 9 cost utility analysis and applies a threshold cost per quality-adjusted life year (QALY) of 10 £30,000 (NICE, 2013) . For technologies that meet the EoL criteria a threshold of £50,000 per 11 QALY has emerged over time (The Parliamentary Office of Science and Technology, 2015) 12
implying that life-extending QALYs for patients with terminal illnesses are valued 1.7 times 13 more than QALYs gained from all other types of treatment. 14 15 By raising the threshold for, or giving additional weight to, life-extending health gains at the 16 EoL, the supplementary guidance suggests that these health benefits are of greater value (to 17 society) than other types of health gains and that EoL might be considered a special case 18 (Rawlins et al., 2010). However, empirical evidence of societal support for such a claim 19 remains equivocal (Shah, 2017) and there is an opportunity cost to the EoL policy in terms of 20 the health gains that would have arisen if spending had been allocated in other ways (Collins 21 and Latimer, 2013) . In this study, we examine societal preferences for provision of life-22 extending treatments for people with a terminal illness using two types of survey question, 23 presenting respondents with choices between 'Decision Rules' (designed to reflect policies 24 of the type that might be applied by national HTA organisations) and 'Treatment Choices' (of 1 the kind that might be made by a regional health board with a fixed budget). This hypothesis is supported by the findings of the first phase of a two-phase study (funded 20 by the Medical Research Council (MRC) Methodology Panel: project ID number G1002324) 21 that used Q methodology to understand the nature of UK societal perspectives around the 22 relative value of life extensions for people with a terminal illness (McHugh et al., 2015) . Q 23 methodology combines qualitative and quantitative methods to study 'subjectivity' -1 opinions, beliefs or values (Stephenson, 1953; Watts and Stenner, 2012) . Data collection is 2 via a card sort, and by-person factor analysis enables shared views around a given topic to 3 be identified and then described; this methodology has previously been applied to the field 4 of health (Baker et al., 2006; van Exel et al., 2015) . Using this methodology we identified 5 three viewpoints: i) 'A population perspective -value for money, no special cases', ii) 'Life is 6 precious -valuing life-extension and patient choice', iii) 'Valuing wider benefits and 7 opportunity cost -the quality of life and death'. These viewpoints (described in detail in the 8 original paper) highlight the plurality of views that exist in society around this topic and 9 indicate that current NICE EoL policy may find little support. The viewpoints in this first 10 phase of work are based around statements of opinion, principles and values relating to the 11 provision of life-extending treatments at the EoL. As such, they are more abstract than 12 most preference elicitation tasks, which tend to describe specific (albeit hypothetical) 13 choices and trade-offs. A clear strength of preference elicitation studies is that opportunity 14 cost is presented in terms of the choice foregone or through WTP (both imply budget 15 constraints). However, preference elicitation scenarios are often attribute-based, can be 16 brief or unrealistic and support for policy tends to be inferred by aggregating responses to 17 these tasks. In the context of EoL, preference elicitation studies have resulted in such mixed 18 respondents agreed with the policy implications of their responses to stated preference 7 tasks. Respondents were first asked to make choices between pairs of scenarios that were 8 either abstract or 'real-world' resource allocation decisions (the latter included qualitative 9 descriptions of patients' quality-of-life and information about the ages of patients instead of 10 conceptual diagrams depicting information about patients, medical conditions and 11 treatments as used in the former), and then were asked to state their agreement (or not) 12 with the implied policy implication of their choice. Results suggested that some respondents 13 struggled to align their views with the need to make specific trade-offs around prioritisation 14 decisions and that disagreement with the policy implications of their choice could result 15 from respondents differing interpretation of policies. These results imply that responses to 16 specific choices and trade-offs may not align with more general beliefs or views around life-17 extending EoL treatments and that further exploration of this could help us understand the 18 mixed, empirical EoL findings. 19
20
In this paper we examine responses to specific choices as well as agreement with more 21 abstract viewpoints in relation to the provision of life-extending treatments for people with 22 a terminal illness ('terminal illness' and 'EoL' are used interchangeably as the NICE 23 supplementary guidance uses the term 'EoL' (NICE, 2009 ) and their definition implies 24 'terminal illness'). Respondents were asked to make choices framed with respect to policies 1 at a national level ('Decision Rule') and treatment provision at a regional level ('Treatment 2 Choice'). One scenario in each case is designed to mirror NICE EoL guidance. We elicit 3 respondents' support for the societal viewpoints identified in our earlier Q methodological 4 work (McHugh et al., 2015) . We then examine how choices between Decision Rules and 5
Treatment Choices correspond to each other and to the wider societal viewpoints. 6
Methods 7
Survey Design

8
The survey was split into different versions, one of which incorporated the Decision Rule 9
and Treatment Choice questions. In addition to these policy choice questions (described in 10 more detail below) respondents were asked to give Likert scale responses (Viewpoint 11 Questions) to indicate (dis)agreement with the three viewpoints identified in McHugh et al. 12 (2015) . The questionnaire concluded with socio-demographic questions. Appendix 1 shows 13 the script used in the introductory animation and Appendices 2-4 detail the text of each 14 question (accessed online at: http://www.gcu.ac.uk/endoflife/onlinesurvey/). 15
16
Decision Rule Design 17
The Decision Rule (D) question (see Appendix 2) was designed to represent the types of 18 high-level rules applied to coverage decisions, at a national level, by bodies like NICE and the 19 Scottish Medicines Consortium (SMC) in the UK. Specifically, respondents were asked to 20 select how a health system should assess drugs for terminally ill patients that would not 21 pass a standard 'value for money' (VFM) test (used as a lay term for cost effectiveness -see 22 'Notes' in Appendix 2 for definition). Respondents were then presented with a choice 1 between three mutually exclusive policies: DA -a standard VFM test applied to all new 2 health technologies ('DA -standard VFM test'); DB -permitting 'special consideration' (i.e. 3 provision of treatments even if the VFM is not passed) for all EoL treatments ('DB -special 4 consideration EoL'); and DC, permitting special consideration to specific categories of new 5 treatments for terminal illnesses, such as those that extend life only or improve QoL only 6 ('DC -EoL ….. it depends'). DC is most like the NICE EoL supplementary guidance for those 7 respondents selecting life extension as the specific reason for special consideration. 8 9
Treatment Choice Design 10
The Treatment Choice question (see Appendix 3) was designed to represent the types of 11 decision that might be faced by Health Boards or Clinical Commissioning Groups, confronted 12 with a fixed, additional budget. Respondents first selected their most-preferred treatment 13 (A-C) then their second-best treatment and following this one reason (from a closed set of 14 options) for their choice of most-preferred treatment. Next, respondents were presented 15 with two PTO questions (pairing their most-preferred versus second-best treatments and 16 their most-preferred versus least-preferred treatments). TA -improving quality-of-life for 17 100 patients with a non-terminal illness (TA -Non-EoL-QoL) episodically for the rest of their 18 life; TB -extending life by three months for 100 EoL patients (TB -EoL-LE), and TC -19 improving symptoms for 100 patients in the last year of their life (TC -EoL-QoL). The size of 20 the health gain from TA, TB and TC was implied rather than explicitly stated within the 21 treatment descriptions. 22
The PTO questions required respondents to choose between providing treatment to one of 1 two patient groups in the context of a fixed budget (only one patient group could be 2 treated); the number of patients in each group was initially set as equal (100). Respondents 3
were then asked to imagine that the cost of their preferred treatment changed, meaning 4 fewer patients could be treated in their preferred group, while the other treatment could 5 still treat 100 patients. The number of patients in their preferred treatment group was 6 altered between low and high numbers of treated patients, until a point of indifference was 7 reached (Nord, 1995). 8 9
Viewpoint Questions Design 10
The Viewpoint Questions were designed to measure respondents' agreement with one of 11 three viewpoints, identified in earlier, in-depth research using Q methodology. The first 12 viewpoint -'A population perspective -value for money, no special cases' -is a broadly 13 utilitarian, system-level perspective. Importance is given to maximizing the health benefits, 14 from a fixed health budget, to a population. Accordingly treatments that yield greatest 15 health improvements in relation to cost should be prioritized and all patient groups should 16 be considered equally deserving of treatment. The second viewpoint -'Life is precious -17 valuing life-extension and patient choice' -is an individual patient perspective and is based 18 on rights-based arguments and views about entitlement. Human life is considered precious 19 and treatments should not be denied because of cost. Consequently no treatments are 20 viewed as being a special case, rather the key criteria is that if a patient wants a treatment, 21
including life-extending treatments at the EoL, they should have it because everyone 22 contributes to the funding of the NHS. The third viewpoint -'Valuing wider benefits and 23 opportunity cost -the quality of life and death' -is similar to the first as it recognizes the 24 importance of achieving value for money from the health budget. However, this viewpoint 1 also appreciates that there may be value for patients and their families from receiving 2 treatment that goes beyond the measurable health benefits typically used in standard cost-3 benefit calculations. For more detail on these viewpoints see McHugh et al. (2015) . The survey was structured as follows: first, a short animated video (created specifically for 20 this project) introduced and set the context for the survey (see 21 http://www.gcu.ac.uk/endoflife/onlinesurvey/introductoryanimation/). The video 22 describes, in simple terms, the issues of scarcity and opportunity cost within the NHS and 23 the need to make decisions about the provision of treatments and services. It explains that 24 many different things could be considered when making decisions about how best to 1 allocate resources, such as severity of illness or quality-of-life, and that in this research the 2 focus was on treatments that help terminally ill patients live longer (see Appendix 1) . 3 4 Following the introduction, the 18 Viewpoint Questions were presented followed by the 5 Decision Rule and then Treatment Choice questions. The survey finished with a number of 6 socio-demographic questions. 7 8 Data Analysis
9
As online surveys are susceptible to 'clicking through' and to respondents being distracted, 10 those who completed the survey very quickly (less than 7 minutes and 30 seconds) or very 11 slowly (longer than 2 hours) were excluded from the analysis. Respondents who completed 12 the survey in less than 7 minutes and 30 seconds, were considered to have reached 13 completion too quickly to have fully read and understood the tasks. Similarly, those 14 respondents who took more than 2 hours to reach completion, might not have fully 15 engaged with the survey and the time taken to complete may have inhibited their ability to 16 recall the premise of the survey outlined in the introductory video. It is possible that, by 17 imposing these rules, valid responses were excluded. However, these conservative cut-off 18 times were based on the judgment of the research team informed by timed testing of the 19 survey. Sensitivity analysis was conducted to examine the impact of imposing these 20 exclusions on findings. 21 22 Summary statistics detailing frequencies for both the Decision Rule and Treatment Choice 1 questions were calculated. Hypotheses about which choice of treatment would logically 2 follow from respondents' decision rule are shown in Table 1 DA would be more likely to choose Treatment Choice TA as this choice reflects a preference 8 for maximizing health gains from a fixed budget. Respondents selecting DB favour all 9 treatments for terminal illnesses so are likely to choose TB or TC. Similarly these two 10 treatments -TB and TC -are also likely to be selected by those who prefer DC. 11 12 PTO ratios were calculated, reflecting respondents' strength of preference for treatment 13 choices. While there is no single, correct approach for aggregating PTO ratios, there is 14 consensus that one method -calculating the 'mean of ratios' -should be avoided. Following The relationship between respondents' decision rule and treatment choices and their 20 viewpoints was also hypothesised (see Table 2 ). Similar predictions (as detailed in Table 1 ) 21 were made about which choices of decision rule and treatment choices would logically 1 follow from respondents' viewpoints. 2 3 
Yes
No Yes No
Viewpoint 2 (Life is precious: valuing lifeextension and patient choice)
No
Unclear Unclear
Viewpoint 3 (Valuing wider benefits and opportunity cost: the quality of life and death)
Unclear
If choices reflect viewpoints then respondents associated with Viewpoint 1 (a broadly 6 utilitarian account) would be more likely to choose Decision Rule DA and Treatment Choice 7 TA because these choices would maximize health benefits. Respondents associated with 8 Viewpoint 2 believe that patient choice is paramount and life is precious, and that cost 9
should not drive decisions about treatment provision so no clear decision rule or treatment 10 choice preference follow. We might predict, however, that those holding Viewpoint 2 11 would object to a strict value for money approach that overrules patient choice on the 12 grounds that they reject consideration of cost. Respondents who agree most with 13 Viewpoint 3 are likely to prefer DC, TA and TC as quality-of-life is reflected in these choices; 14 DA could also be chosen because of value for money concerns but may be considered too 15 narrow a decision rule for this account. representative with respect to age, gender, SEG and ethnicity. 1,657 respondents were 9 randomly allocated to the Policy Choice Version; after exclusion of respondents based on 10 completion times the Policy Choice Version totaled 1,496 (Table 3 details 
Relationship between policy choices and respondent characteristics
16
The relationship between respondents' socio-demographic characteristics and their policy 17 choices (Decision Rule and Treatment Choice) is shown in Table 3 . Respondents' gender, 18 age, ethnicity, SEG, education and income were statistically significantly related to their 19 choice of Decision Rule. Males were more likely to choose DA and females to choose DC; 20 those selecting DB were younger than those selecting DA or DC and more-likely to be non-21 white; those with high educational qualifications, socio-economic status and income more 22 often selected DA whereas respondents with low qualifications and income more often 1 chose DB. Responses to Treatment Choice questions appeared to be related to gender, age, 2 and education but in general, there were fewer statistically significant relationships. Males 3 were more likely to choose TB and females to choose TC; those selecting TB were younger 4 than those selecting TA or TC; and those with low educational qualifications chose TB 5 whereas those with high qualifications selected TA. 6 7 3 4
Decision Rule Results
1 Table 4 shows the results from the Decision Rule question. DB was the least popular policy 2 when respondents were asked 'which one of the following policies do you agree with 3 most?', and overall there was a preference for giving special consideration to treatments for 4 terminal illnesses in some (albeit not all) situations. Of the 669 respondents who selected 5 DC, a large majority (72%) stated that treatments that improve quality-of-life for terminally 6 ill patients should be given special consideration; only 10% stated special consideration 7 should be given to treatments that extend life. When asked about the role cost should play 8 in the provision of DB or DC, 56% of the 293 respondents who preferred DB thought this 9 policy should be implemented regardless of cost, whereas 63% of the 669 respondents who 10 preferred DC agreed there should be some limit to the amount the NHS pays to implement 11 this policy. 12 13 improving treatment for non-terminal illness (Non-EoL-QoL)). A substantial number of 5 respondents (43%) preferred TC (quality-of-life-improving treatment for a terminal illness 6 (EoL-QoL)); only 6% preferred TB (life-extending treatment for a terminal illness (EoL-LE)). 7
Examination of second-choice treatments reveals that TB (EoL-LE) remains the least-8 preferred treatment, while more respondents prefer TC (EoL-QoL) (48%) to TA (Non-EoL-9
QoL) (35%). The majority of respondents placed TB in third place (78%), whereas TC was 10 ranked third by the least number of respondents (9%). 11 12 
14
Respondents also chose one reason for selecting their preferred choice of treatment. 15
Respondents who most-preferred TA did so because it would provide a larger health benefit 16 gain (34%), it would improve quality-of-life (26%) and the illness affects patients for the rest 17 of their life (22%). Quality-of-life improvement was also the primary reason behind the 18 preferred selection of TC (77%). Those preferring TB did so mainly because it would extend 19 life (50%). 20 1 PTO Results 2 PTO questions paired respondents' most-preferred versus second-best treatment (1 vs. 2) 3 and most-preferred versus least-preferred treatment (1 vs. 3); the totals in Table 5 detail 4 the aggregated order in which each of the three treatments was ranked. Data from both 5 PTO questions -1 vs. 2 and 1 vs. 3 -were combined in order to aggregate responses for 6 each pair of treatments -TA and TB, TA and TC and TB and TC. Counts, ratios and 'extreme 7 preferences' (taken as the number of respondents who consider that fewer than 10 patients 8 receiving one treatment is equivalent to 100 patients receiving the other) are shown in 9 
While the initial ranking of treatments (see Table 5 ) indicates the ordering of treatments, 15 examination of PTO data provides insight into the magnitude of preferences between pairs 16 of treatments. For the pair TA versus TC both (the 'ratio of means' and the 'median of ratios') are close to one, suggesting that respondents value the two treatments similarly 1 (0.93 and 0.98). Ratios indicate greater strength of preference for TA or TC when compared 2 to TB. 3 4
In an attempt to 'unpack' the data a little, Table 6 also shows 'extreme preferences'. While a 5 substantial proportion of respondents' make these extreme choices, the most pronounced 6 differences are seen in the pairings when either TA or TC is set against TB (59% v 44% and 7 60% v 42%). In pair TA versus TC, despite ratios suggesting a slight preference for TA over TC 8 there is a greater proportion of extreme preferences among respondents who prefer TC 9 than those who prefer TA (51% vs. 44%). This is balanced against the fact that a greater 10 number of respondents prefer TA. Table 7 cross-tabulates Decision Rule and Treatment Choices. As hypothesised (see Table  18 1), those who selected DA more often chose TA (70%) and to a lesser extent TC (27%); TB 19 was rarely chosen. Those who selected DB most commonly chose TC (57%), as predicted, 20 but, unexpectedly, more DB respondents selected TA (33%) than chose TB (10%). This 21 pattern of response was the same for DC respondents: most chose TC (50%) as expected but 22 a large number selected TA (44%) over TB (6%). This latter result is not wholly surprising, 23 though, given that the majority of respondents who chose DC stated special consideration 1 depends on improvements in quality-of-life (see Table 4 ). 2 3 The results in Table 8 show that 37% of respondents were matched with Viewpoint 1 ('A 7 population perspective -value for money, no special cases'). Just under half of the 8 respondents (49%) were matched with Viewpoint 2 ('Life is precious -valuing life-extension 9 and patient choice') and 9% matched with Viewpoint 3 ('Valuing wider benefits and 10 opportunity cost -the quality of life and death'). 11 12 Table 8 shows a statistically significant pattern between respondents' viewpoints and their 13 policy choices; this pattern broadly reflects the hypotheses outlined in Table 2 . Respondents 14 associated with Viewpoint 1 were more likely to choose Decision Rule DA (56%) than DC 15 (36%) or DB (8%) and, also as predicted, favour Treatment Choice TA (69%). Predictions 16 were more difficult for Viewpoint 2 for reasons already mentioned. However, as expected, 17 DA, which proposes a strict value for money approach, was the least preferred decision rule 18 for those associated with Viewpoint 2 (17%). Unexpectedly respondents who were 19 associated with Viewpoint 3 were more likely to select DA (53%) then DC (36%); few chose 20 DB (11%). As predicted Viewpoint 3 respondents were more likely to choose a quality-of-life 21 improving treatment -TA (62.4%) or TC (36%) -than one that extends life TB (2%). Discussion 10 This paper reports the findings of a national survey of the UK general population 11 investigating societal preferences for provision of life-extending treatments for people with 12 a terminal illness framed with respect to policies at a national level (Decision Rule) and 13 treatment provision at a regional level (Treatment Choice). Results challenge NICE's current 14
EoL guidance as there is very little support for prioritising life-extending treatments for 15 terminal illnesses over and above other treatments. Substantial support is found for quality-16 of-life improving treatments at the EoL and for policies which account for the costs of new 1 treatments. 2 3 While Decision Rule findings showed the majority of respondents supported giving special 4 consideration to assessing treatments for terminal illnesses (taking DC and DB together), 5 this finding was qualified. More support was given to DC, which suggests that special 6 consideration should be given to terminal illnesses in health care priority setting only in 7 certain situations; with a focus on treatments that improve quality-of-life. Faced with 8 Treatment Choices, respondents prioritised quality-of-life over life extension with 9 preference for TA and TC over TB which aligned with the strength of preference results for 10 these pairings; PTO results also indicated a substantial proportion of respondents made 11 limited trade-offs (extreme preferences). Examining agreement with the three societal 12 viewpoints indicated that our sample disagreed regarding the role cost should play in 13 decision-making. While 49% of respondents were assigned to Viewpoint 2, an account that 14 suggests that costs should not play a role in decision making, 46% of respondents 15 (Viewpoint 1 and 3) recognized the importance of achieving value for money. 16 17
Exploration of the relationship between different Decision Rules and Treatment Choices 18
found encouraging results as we observe broad consistency between respondents' 19 preferences elicited from those choices. An unexpected observation was the proportion of 20 respondents who selected Decision Rules that gave EoL treatments special consideration 21 and preferred the Non-EoL-QoL health maximizing treatment (TA) (33% of those selecting 22 DB and 44% of those selecting DC). This could be explained by the health gains of TA arising 23 over patients' lifetimes and so respondents might reasonably have interpreted these as far 24 exceeding the health gains likely to arise from 100 patients receiving either TB or TC. While 1 this could indicate a disconnect between different types of preference, it could also be the 2 case that preference for EoL is outweighed if the health gain from the alternative treatment 3 is substantial. Unfortunately the online nature of our survey meant these issues could not 4 be explored qualitatively. 5 6 Examining the pattern of response between respondents' viewpoints and their choices 7 indicates that while in the majority of cases there is a pattern in line with expectations; it is 8 not always the case. However, a priori hypotheses are not straightforward because 9
viewpoints are wider and take in other issues, and choices were designed to examine 10 support for NICE EoL policy rather than to mirror viewpoints exactly. Despite this limitation, 11 interesting findings emerged. Results suggest that when respondents make choices they are 12 more attuned to the limits of the NHS budget than when responding in more general terms 13 when opportunity cost is not always explicit (Viewpoint Questions). More research is 14 needed to examine the nature of consistency between principles, policies and choices, if 15 policy is to be designed in areas of societal disagreement. As well as future work 16 qualitatively exploring inconsistencies, the separation of preferences into different 'levels' -17 principles, policies and choices -of specificity and abstraction would enable examination of 18 why and how respondents (dis)agree and whether there is potential for agreement in more-19 specific cases in the face of disagreement at the level of theory or principle (Sunstein, 1995) . This is an important observation given that media reports and other policy initiatives (e.g. 9
Cancer Drugs Fund) might suggest that society values life-extending treatments above other 10 treatments and services competing for funds. If additional societal benefits are not 11 generated from prioritising funding for life-extending treatments at the EoL, then cost-12 effective treatments for non-EoL patients may be displaced by policies that prioritise less 13 efficient treatments. 14
15
Limitations
16
There are a number of limitations to the study design and details of the survey that should 17 be acknowledged. Firstly, respondents were quota-sampled to represent the general 18 population with respect to standard socio-demographic variables, but they were members 19 of YouGov's online survey panel, which introduces self-selection bias. Furthermore, a trade-20 off of undertaking large scale survey work is that we were unable to collect qualitative data 21 alongside the main survey. As such, we could not explore qualitatively: why, in some cases, 22 the relationships between Decision Rule and Treatment Choice responses, or between 23 policy choices and viewpoints, were not as expected; whether and to what extent 1 respondents viewed TA (Non-EoL-QoL) as the health maximizing treatment; nor 2 respondents' rationales for their treatment choices to move beyond the circularity of re-3 stating details of the scenarios chosen. 4 5 Secondly, question ordering may have affected responses. We took the view that there was 6 need for a consistent ordering as Viewpoint Questions introduce different issues related to 7 the topic, and Treatment Choice selection was considered to flow more naturally from the 8 choice of a high-level Decision Rule, but we cannot rule out the ordering effects that may 9 have followed from this design. 10 11 Thirdly, the Decision Rule question could have introduced a 'status quo' framing effect by 12 stating that the NHS currently applies a 'value for money' test before agreeing to provide 13 new medicines. Thus respondents might have seen this as a choice between the status quo 14 (DA) and something new -DB or DC -although the status quo is in reality closer to DC 15 (along with a preference for life extension). Respondents could have been unwilling to 16 choose a policy that contradicts the current agenda. However, our results show that DC 17
(with a quality-of-life preference) was the most popular choice. 18 19 Fourthly, as shown in (NICE, 2017) . Whilst this could have led to different interpretations amongst 5 respondents, we were given no indication of this during the piloting phase and the decision 6 rule and treatment choice scenarios all refer to 'treatments'. The focus on treatments is 7 similar to the approach used in the EoL preference elicitation literature summarized in the 8 'Background' section. However, whether 'treatment' refers to drugs or something else is 9 generally unstated in these papers; exploring preferences for different types of treatment at 10 the EoL could be an interesting source of future research. 11 2. The NHS spends its budget on many things, including doctors, nurses, beds, new drugs 7 and treatments. 8
3. Although the health service budget is very big, it is still a fixed amount. There is never 9 enough money to do everything we want. 10 4. Of course, the NHS budget could grow in the future. 11 5. But this research is about the money the health service has now, and the best way to 12 spend it. 13
6. Because the budget is fixed, difficult decisions have to be made about how to spend NHS 14 money. 15 7. When the NHS provides a service, the public benefits. But the public will not benefit if 16 that service is not funded. 17
8. Because of this, and because the public pays for the NHS through its taxes, it is important 18 that decisions on how to spend NHS money take into account the views of the public. 19
9. For example, thinking generally about all NHS patients, should we concentrate our 20 funding on the treatment of people who are most severely ill? Or perhaps we should focus 21 our spending on treatments that give people a better quality of life? Or should we prioritise 22
the funding of treatments that help people to live longer? 23
10. In this research project, our focus is on NHS treatments that help terminally ill patients 24 live longer. 25 11. These treatments will not cure the person's illness, but will extend their life, usually by 26 weeks or by months. 27
12. Whatever money is spent on these treatments is not then available to spend elsewhere 28 in the NHS. 29
13. Because of this, the cost of treatments for terminally ill people, and how much good 30 they do, has to be considered in relation to all other NHS spending. 31
14. These are difficult decisions to make, and there are no right or wrong answers. 32 15. As a member of the public, we need to know your views on this important topic. 33 Appendix 2 Decision Rule Question 1 2 *italics highlight programming notes* 3 4
As there is a limit to the health budget, the NHS applies a 'value for money test' before 5 agreeing to provide new medicines. This test looks at the extra costs and the health benefits 6
of new medicines compared with the best treatments already provided by the NHS, for that 7 condition. 8
The value for money test makes sure the NHS does not spend money on high cost 9
treatments, which provide only limited health benefits, but funds those treatments that 10 deliver better value for money. 11
There are some drugs, for terminally ill patients, which do not pass this value for money 12 test, because they do not cure patients. New treatments that extend life for terminally ill patients should be given special consideration.
POLICY C2
New treatments that improve quality of life for terminally ill patients should be given special consideration. Treatments that extend life for terminally ill patients should be given special consideration (but not if their quality of life will be poor).
POLICY C3
New
POLICY C3b
Treatments for patients who have only known that they were terminally ill for a short time should be given special consideration.
POLICY C3c
Treatments for terminally ill patients who have not had their fair inningsin terms of the length of their life should be given special consideration.
POLICY C3d
Treatments for terminally ill patients should be given special consideration if .
. . . . 
Please type in
TREATMENT A
Patients are currently suffering from a non-life threatening illness that causes them discomfort and fatigue. The illness also reduces their mobility and ability to undertake their usual activities. This occurs a few times throughout every year for the rest of their life. Each episode lasts for up to 2 weeks.
A new treatment is available that will reduce their symptoms and make patients feel better, improving their quality of life for the rest of their life.
Funding will mean that 100 patients can be treated in the next year.
TREATMENT B
Patients are currently suffering from a terminal illness that causes them discomfort and fatigue. The illness also reduces their mobility and ability to undertake their usual activities.
A new treatment is available for terminally ill patients in the last year of their life. The treatment will extend patients' lives by three months. It will not improve their quality of life.
TREATMENT C
A new treatment is available for terminally ill patients in the last year of their life. The treatment will reduce their symptoms and make patients feel better, improving their quality of life. It will not extend their life.
Q1. Which treatment should be provided? Click on the 'Treatment' you think should be  1  provided.  2  3 Now from the remaining two treatments click on the 'Treatment' you think should be 4 provided.
6
Show the treatments on the screen in the order the respondent preferred them 7 8
If only one treatment could be funded, you said that Treatment (insert most preferred) 9
should be provided. 10 11
Treatment (insert second most preferred) was your next most preferred after treatment 12
(insert most preferred Q3a. Your 'preferred treatment' from Q1 was Treatment 'insert letter of preferred 1 treatment' and your 'second-best treatment' was Treatment 'insert letter of second-best 2 treatment'. Only one treatment can be funded. 3 4
Suppose the cost of your 'preferred treatment', Treatment 'insert letter of preferred 5 treatment', has now changed, and fewer patients can be treated as a result. 6 7
While your 'second-best treatment', Treatment 'insert letter of second-best treatment', will 8 still treat 100 patients, (if funded), the number of patients that your 'preferred treatment', 9
Treatment 'insert letter of preferred treatment', is now less. 10 11
When 100 patients could be funded by each treatment, you chose to fund Treatment 'insert 12
letter of preferred treatment. Treatments should be directed towards people who have a greater chance of survival.
5.
At the end of their life, patients should be cared for at home with a better quality of life rather than have aggressive and expensive treatments that will only extend life for a short period of time.
26.
It is wrong to raise hopes and expectations by making a special case for treatments that will only extend life by a short time.
38.
The health system should be about getting the greatest benefit overall for the population.
2.
We should support an individual patient's choice for treatments that give short life extensions.
13.
I would place more value on end-of-life treatments than many medical treatments for nonterminal conditions.
Viewpoint 2
17. If a life-extending treatment for terminally ill patients is expensive, but the only treatment available, it should still be provided.
20.
We all have the right to life.
27.
To extend life in a way that is beneficial to the patient is morally the right thing to do.
37.
All human life is precious.
1.
It is not worthwhile devoting more and more NHS money to someone who is going to die soon anyway.
33.
End-of-life drugs are not a cure, they are life-prolonging. There is no point in delaying the inevitable for a short time.
Viewpoint 3
25.
We should spend proportionately more on patients when we feel those patients have not had their fair innings -in terms of the length of their life or the quality of that life.
31.
Treatments that are very costly in relation to their health benefits should be withheld.
34.
Patients at the end of life will grasp any slightest hope but that is not a good reason for the NHS to provide costly treatments that may extend life by a short time.
41.
I wouldn't want my life to be extended just for the sake of it -just keeping breathing is not life.
23.
A year of life is of equal value for everyone.
24.
You can't put a price on life.
*Grey shaded statements are negatively associated with the viewpoint.* 3
